Latest Conference Articles

Bisphosphonate Use Associated with Increased Fracture Risk

Bisphosphonate Use Associated with Increased Fracture Risk

September 16th 2020

ASBMR

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

Teriparatide for Bone Formation in Hip Fractures

Teriparatide for Bone Formation in Hip Fractures

September 16th 2020

ASBMR

Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.

Zoledronate As Booster Drug in Fight Against Osteoporosis

Zoledronate As Booster Drug in Fight Against Osteoporosis

September 14th 2020

ASBMR

Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.

Q&A:  Vitamin D and Bone Mineral Density

Q&A: Vitamin D and Bone Mineral Density

September 14th 2020

ASBMR

High-dose vitamin D supplementation compared with standard-dose vitamin D supplementation resulted in a greater loss of volumetric bone mineral density in women but not men, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

Q&A:  Anabolic Agents for Osteoporosis

Q&A: Anabolic Agents for Osteoporosis

September 14th 2020

ASBMR

Three months of treatment with the osteoporosis drug abaloparatide (Tymlos, Radius) has a robust effect on bone formation in postmenopausal women with osteoporosis, according to a study presented on Sept. 12 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

Sarilumab Shown to Reduce Persistent Pain in RA

Sarilumab Shown to Reduce Persistent Pain in RA

September 11th 2020

CCR

Report shows that sarilumab may be better at controlling severe and refractory pain in rheumatoid arthritis patients than adalimumab.

JAK1 Inhibitor Filgotinib Meets PsA Safety Profile

JAK1 Inhibitor Filgotinib Meets PsA Safety Profile

September 11th 2020

CCR

The investigational JAK inhibitor filgotinib―which is under study as a treatment for a number of rheumatic diseases―has been shown to be safe and well tolerated in psoriatic arthritis patients.

Abaloparatide Shown to Increase Bone Mineral Density

Abaloparatide Shown to Increase Bone Mineral Density

September 11th 2020

ASBMR

The osteoporosis treatment abaloparatide has been shown to increase bone mineral density of the lumbar spine, total hip and femoral neck bone in patients with osteoporosis who are at high risk for fracture, according to a study presented today at the American Society for Bone and Mineral Research annual meeting which is being held virtually through Tuesday.

EULAR Report: Physicians Increasingly Pass on Biosimilars

EULAR Report: Physicians Increasingly Pass on Biosimilars

June 16th 2020

EULAR

Rheumatologists still lack confidence in prescribing biosimilars, shows study presented at EULAR.

EULAR Report: Nurse-Led Care May Improve RA Patient-Reported Outcomes

EULAR Report: Nurse-Led Care May Improve RA Patient-Reported Outcomes

June 16th 2020

EULAR

Rheumatoid arthritis patients receive treatment that is on par with that of a physician, shows a study based on patient-reported outcomes and disease activity. The study was recently reported at the EULAR annual meeting.